Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.
Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.